DBV Technologies S.A. (NASDAQ:DBVT) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• DBV Technologies S.A. has received a consensus rating of “Moderate Buy” from five analysts, with one sell, three buy, and one strong buy recommendation.
• The average 12-month price target for the stock is $14.75, with JMP Securities setting a target of $21.00 and Goldman Sachs at $7.25.
• In the latest quarterly earnings, DBV Technologies reported a loss of ($1.55) per share, significantly missing analysts' estimates of ($0.21).

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.75.

Several equities research analysts recently commented on the stock. The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a research report on Thursday, May 29th. Wall Street Zen lowered shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective on shares of DBV Technologies in a research report on Thursday, June 26th. Lifesci Capital upgraded shares of DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. Finally, Citigroup restated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th.

DBV Technologies Trading Down 0.8%

Shares of NASDAQ:DBVT traded down $0.08 on Wednesday, reaching $9.87. 18,275 shares of the company were exchanged, compared to its average volume of 32,958. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The firm has a market cap of $270.44 million, a price-to-earnings ratio of -2.07 and a beta of -0.36. The company has a 50-day moving average of $9.73 and a 200-day moving average of $8.49.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%.The business had revenue of $1.74 million during the quarter, compared to analysts' expectations of $0.64 million. As a group, analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP purchased a new position in DBV Technologies in the 2nd quarter valued at about $9,315,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies in the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC purchased a new position in shares of DBV Technologies during the 2nd quarter worth about $9,649,000. Vivo Capital LLC purchased a new position in shares of DBV Technologies during the 2nd quarter worth about $9,659,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in shares of DBV Technologies during the 2nd quarter worth about $340,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.